Join
Live feed
·
PRReleasevia Quantisnow
Neurocrine Biosciences Inc. logo

Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale

ByQuantisnow·Wall Street's wire, on your screen.
NBIX· Neurocrine Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NBIX (Neurocrine Biosciences Inc.) and more on Quantisnow.